Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy La Jolla Pharmaceutical stock
Learn how to easily invest in La Jolla Pharmaceutical stock.
La Jolla Pharmaceutical Co is a biotechnology business based in the US. La Jolla Pharmaceutical shares (LJPC) are listed on the NASDAQ and all prices are listed in US Dollars. La Jolla Pharmaceutical employs 61 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in La Jolla Pharmaceutical
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LJPC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- LJPC shares summary
- Compare share dealing platforms
- Is LJPC stock a buy or sell?
- Stock performance over time
- Are LJPC shares over-valued?
- La Jolla Pharmaceutical's financials
- How volatile are LJPC shares?
- Does La Jolla Pharmaceutical pay a dividend?
- Have LJPC shares ever split?
- Other common questions
La Jolla Pharmaceutical stock price (NASDAQ: LJPC)Use our graph to track the performance of LJPC stocks over time.
La Jolla Pharmaceutical shares at a glance
|Latest market close||$3.12|
|52-week range||$3.10 - $5.08|
|50-day moving average||$3.76|
|200-day moving average||$4.13|
|Wall St. target price||$4.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.16|
Buy La Jolla Pharmaceutical shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy La Jolla Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
La Jolla Pharmaceutical price performance over time
|1 week (2022-06-24)||-9.83%|
|1 month (2022-06-02)||-18.96%|
|3 months (2022-03-29)||N/A|
|6 months (2021-12-29)||-32.90%|
|1 year (2021-07-02)||-27.61%|
|2 years (2020-07-02)||-29.25%|
|3 years (2019-07-02)||9.51|
|5 years (2017-06-30)||29.77|
Is La Jolla Pharmaceutical stock undervalued or overvalued?
Valuing La Jolla Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of La Jolla Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
La Jolla Pharmaceutical's P/E ratio
La Jolla Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, La Jolla Pharmaceutical shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
La Jolla Pharmaceutical's EBITDA
La Jolla Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.1 million.
The EBITDA is a measure of a La Jolla Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
La Jolla Pharmaceutical financials
|Revenue TTM||$52 million|
|Operating margin TTM||4.68%|
|Gross profit TTM||$63.1 million|
|Return on assets TTM||1.64%|
|Return on equity TTM||0%|
|Market capitalisation||$79.7 million|
TTM: trailing 12 months
La Jolla Pharmaceutical share dividends
We're not expecting La Jolla Pharmaceutical to pay a dividend over the next 12 months.
Have La Jolla Pharmaceutical's shares ever split?
La Jolla Pharmaceutical's shares were split on a 1:50 basis on 13 January 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your La Jolla Pharmaceutical shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for La Jolla Pharmaceutical shares which in turn could have impacted La Jolla Pharmaceutical's share price.
La Jolla Pharmaceutical share price volatility
Over the last 12 months, La Jolla Pharmaceutical's shares have ranged in value from as little as $3.1 up to $5.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while La Jolla Pharmaceutical's is 1.9578. This would suggest that La Jolla Pharmaceutical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
La Jolla Pharmaceutical overview
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. .
Frequently asked questionsWhat percentage of La Jolla Pharmaceutical is owned by insiders or institutions?
Currently 1.418% of La Jolla Pharmaceutical shares are held by insiders and 68.804% by institutions. How many people work for La Jolla Pharmaceutical?
Latest data suggests 61 work at La Jolla Pharmaceutical. When does the fiscal year end for La Jolla Pharmaceutical?
La Jolla Pharmaceutical's fiscal year ends in December. Where is La Jolla Pharmaceutical based?
La Jolla Pharmaceutical's address is: 201 Jones Road, Waltham, MA, United States, 02451 What is La Jolla Pharmaceutical's ISIN number?
La Jolla Pharmaceutical's international securities identification number is: US5034596040 What is La Jolla Pharmaceutical's CUSIP number?
La Jolla Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 503459505
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert